| Q34305899 | A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults |
| Q89718115 | A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide |
| Q37693929 | Acute promyelocytic leukemia: what are the treatment options? |
| Q37905921 | Advances in therapies for acute promyelocytic leukemia |
| Q40468248 | Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. |
| Q50902018 | Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia. |
| Q41517525 | Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet |
| Q39323997 | Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide. |
| Q39843411 | Autologous transplant remains the preferred therapy for relapsed APL in CR2. |
| Q34764504 | Biology, risk stratification, and therapy of pediatric acute leukemias: an update |
| Q38425422 | Childhood acute myeloid leukemia: an Indian perspective |
| Q35230758 | Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance |
| Q38197074 | Contemporary treatment of APL |
| Q33613426 | Curing all patients with acute promyelocytic leukemia: are we there yet? |
| Q92158117 | Current first- and second-line treatment options in acute promyelocytic leukemia |
| Q38674575 | Current standard treatment of adult acute promyelocytic leukaemia |
| Q37971327 | Current treatment strategy of acute promyelocytic leukemia |
| Q36612619 | Emerging new approaches for the treatment of acute promyelocytic leukemia |
| Q37994088 | How to manage acute promyelocytic leukemia |
| Q37929546 | Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia |
| Q52630962 | Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. |
| Q42749230 | Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. |
| Q64053212 | Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet |
| Q48791883 | Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel |
| Q37908158 | Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible? |
| Q51759775 | Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy. |
| Q33956085 | Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation |
| Q37934964 | Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease |
| Q40475626 | Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report. |
| Q39484903 | Role of arsenic trioxide in acute promyelocytic leukemia |
| Q37785493 | Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review |
| Q51799119 | Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. |
| Q37296118 | The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy |
| Q24193790 | Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer |
| Q24234833 | Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer |
| Q38139992 | Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions |
| Q35640744 | Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide |
| Q37388701 | Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies |
| Q88089968 | [How I treat PML-RARα positive actue promyelocytic leukemia] |